REFERENCES

1. Bloem BR, Okun MS, Klein C. Parkinson’s disease. Lancet 2021;397:2284-303.

2. Tolosa E, Garrido A, Scholz SW, Poewe W. Challenges in the diagnosis of Parkinson’s disease. Lancet Neurol 2021;20:385-97.

3. Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 2015;30:1591-601.

4. Poewe W, Seppi K, Tanner CM, et al. Parkinson disease. Nat Rev Dis Primers 2017;3:17013.

5. Wang Q, Song S, Jiang L, Hon J. Interplay among norepinephrine, NOX2, and neuroinflammation: key players in Parkinson’s disease and prime targets for therapies. Ageing Neurodegener Dis 2021; 1:6.

6. Jankovic J, Tan EK. Parkinson’s disease: etiopathogenesis and treatment. J Neurol Neurosurg Psychiatry 2020;91:795-808.

7. Karabiyik C, Frake RA, Park SJ, Pavel M, Rubinsztein DC. Autophagy in ageing and ageing-related neurodegenerative diseases. Ageing Neurodegener Dis 2021;1:2.

8. Corti O, Lesage S, Brice A. What genetics tells us about the causes and mechanisms of Parkinson’s disease. Physiol Rev 2011;91:1161-218.

9. Deng H, Wang P, Jankovic J. The genetics of Parkinson disease. Ageing Res Rev 2018;42:72-85.

10. Blauwendraat C, Nalls MA, Singleton AB. The genetic architecture of Parkinson’s disease. Lancet Neurol 2020;19:170-8.

11. Jia F, Fellner A, Kumar KR. Monogenic Parkinson’s disease: genotype, phenotype, pathophysiology, and genetic testing. Genes (Basel) 2022;13:471.

12. Paisan-Ruiz C, Bhatia KP, Li A, et al. Characterization of PLA2G6 as a locus for dystonia-parkinsonism. Ann Neurol 2009;65:19-23.

13. Magrinelli F, Mehta S, Di Lazzaro G, et al. Dissecting the phenotype and genotype of PLA2G6-related parkinsonism. Mov Disord 2022;37:148-61.

14. Guo Y, Sun Y, Song Z, et al. Genetic analysis and literature review of SNCA variants in Parkinson’s disease. Front Aging Neurosci 2021;13:648151.

15. Yang J, Roy A, Zhang Y. Protein-ligand binding site recognition using complementary binding-specific substructure comparison and sequence profile alignment. Bioinformatics 2013;29:2588-95.

16. Yang J, Roy A, Zhang Y. BioLiP: a semi-manually curated database for biologically relevant ligand-protein interactions. Nucleic Acids Res 2013;41:D1096-103.

17. Forsell PK, Kennedy BP, Claesson HE. The human calcium-independent phospholipase A₂ gene: multiple enzymes with distinct properties from a single gene. Eur J Biochem 1999;262:575-85.

18. Elsayed LEO, Eltazi IZ, Ahmed AE, Stevanin G. Insights into clinical, genetic, and pathological aspects of hereditary spastic paraplegias: a comprehensive overview. Front Mol Biosci 2021;8:690899.

19. Chu YT, Lin HY, Chen PL, Lin CH. Genotype-phenotype correlations of adult-onset PLA2G6-associated neurodegeneration: case series and literature review. BMC Neurol 2020;20:101.

20. Deng X, Yuan L, Jankovic J, Deng H. The role of the PLA2G6 gene in neurodegenerative diseases. Ageing Res Rev 2023;89:101957.

21. Cheng HL, Chen YJ, Xue YY, Wu ZY, Li HF, Wang N. Clinical characterization and founder effect analysis in Chinese patients with phospholipase A2-associated neurodegeneration. Brain Sci 2022;12:517.

22. Zou Y, Luo H, Yuan H, et al. Identification of a novel nonsense mutation in PLA2G6 and prenatal diagnosis in a Chinese family with infantile neuroaxonal dystrophy. Front Neurol 2022;13:904027.

23. Malley KR, Koroleva O, Miller I, et al. The structure of iPLA₂β reveals dimeric active sites and suggests mechanisms of regulation and localization. Nat Commun 2018;9:765.

24. Ramanadham S, Ali T, Ashley JW, Bone RN, Hancock WD, Lei X. Calcium-independent phospholipases A₂ and their roles in biological processes and diseases. J Lipid Res 2015;56:1643-68.

25. Larsson PK, Claesson HE, Kennedy BP. Multiple splice variants of the human calcium-independent phospholipase A₂ and their effect on enzyme activity. J Biol Chem 1998;273:207-14.

26. Zhou Q, Yen A, Rymarczyk G, et al. Impairment of PARK14-dependent Ca²⁺ signalling is a novel determinant of Parkinson’s disease. Nat Commun 2016;7:10332.

27. Sánchez E, Azcona LJ, Paisán-Ruiz C. Pla2g6 deficiency in zebrafish leads to dopaminergic cell death, axonal degeneration, increased β-synuclein expression, and defects in brain functions and pathways. Mol Neurobiol 2018;55:6734-54.

28. Kinghorn KJ, Castillo-Quan JI, Bartolome F, et al. Loss of PLA2G6 leads to elevated mitochondrial lipid peroxidation and mitochondrial dysfunction. Brain 2015;138:1801-16.

29. Daida K, Nishioka K, Li Y, et al. PLA2G6 variants associated with the number of affected alleles in Parkinson’s disease in Japan. Neurobiol Aging 2021;97:147.e1-9.

30. Chen YJ, Chen YC, Dong HL, et al. Novel PLA2G6 mutations and clinical heterogeneity in Chinese cases with phospholipase A2-associated neurodegeneration. Parkinsonism Relat Disord 2018;49:88-94.

31. Chiu CC, Yeh TH, Lu CS, et al. PARK14 PLA2G6 mutants are defective in preventing rotenone-induced mitochondrial dysfunction, ROS generation and activation of mitochondrial apoptotic pathway. Oncotarget 2017;8:79046-60.

32. Gui YX, Xu ZP, Lv W, Liu HM, Zhao JJ, Hu XY. Four novel rare mutations of PLA2G6 in Chinese population with Parkinson’s disease. Parkinsonism Relat Disord 2013;19:21-6.

33. Engel LA, Jing Z, O'Brien DE, Sun M, Kotzbauer PT. Catalytic function of PLA2G6 is impaired by mutations associated with infantile neuroaxonal dystrophy but not dystonia-parkinsonism. PLoS One 2010;5:e12897.

34. Bohlega SA, Al-Mubarak BR, Alyemni EA, et al. Clinical heterogeneity of PLA2G6-related Parkinsonism: analysis of two Saudi families. BMC Res Notes 2016;9:295.

35. Lu CS, Lai SC, Wu RM, et al. PLA2G6 mutations in PARK14-linked young-onset parkinsonism and sporadic Parkinson’s disease. Am J Med Genet B Neuropsychiatr Genet 2012;159B:183-91.